EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The need for the GREAT+ score to predict relapse in Graves’ disease: a questionnaire among patients and internal medicine specialists

H I Jansen, C Heuveling van Beek, P H Bisschop, A C Heijboer, E Bruinstroop, A Boelen

Journal of Endocrinological Investigation · 2024

DOI: 10.1007/s40618-024-02358-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von H I Jansen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Endocrine Laboratory, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Graves Disease, Recurrence, Internal Medicine, Antithyroid Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Graves’ disease (GD) is an auto-immune cause of hyperthyroidism. First-line treatment often consists of a 12–18 month course of antithyroid drugs (ATD). After discontinuation of ATD, GD relapses in approximately 50% of patients. The ‘Graves recurrent event after therapy+ ’ (GREAT+) score may predict individual relapse chances after ATD discontinuation more accurately based on clinical and laboratory parameters at diagnosis. We investigated the need for the GREAT+ score through an online questionnaire among GD patients and physicians treating GD.

Methods

An anonymous online questionnaire was distributed to patients and physicians between June 2022 and August 2023.

Results

The questionnaire was completed by 532 patients and 44 physicians. Results showed that 94% of patients were interested in knowing their GREAT+ score at the start of treatment. 55% would consider definite treatment (radioiodine/thyroidectomy) as first-line treatment in case of a high relapse chance. 98% of the physicians indicated the GREAT + score would support patient counseling. 84% may change their advice for first-line treatment if a patient has a high relapse chance based on the score.

Conclusion

Patients and physicians considered the GREAT+ score as a valuable addition to the current available information which could change treatment decisions. Therefore, external validation of the GREAT+ score is justified to implement this score in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseRecurrenceInternal MedicineAntithyroid AgentsHumansSurveys and QuestionnairesFemaleMaleMiddle AgedAdultPrognosisAgedYoung Adult

Stichwörter der Autor:innen

Antithyroid drugsGraves’ diseasePrediction modelRelapse chance

Substanzen

Antithyroid Agents

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Endocrine Laboratory, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Department of Laboratory Medicine, Endocrine Laboratory, Amsterdam UMC Location University of Amsterdam, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam, The Netherlands.
  • Department of Endocrinology and Metabolism, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands.
  • Department of Laboratory Medicine, Endocrine Laboratory, Amsterdam UMC Location University of Amsterdam, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands. a.boelen@amsterdamumc.nl.

Zitieren

APA

Jansen, H. I., Heuveling van Beek, C., Bisschop, P. H., Heijboer, A. C., Bruinstroop, E., & Boelen, A. (2024). The need for the GREAT+ score to predict relapse in Graves’ disease: a questionnaire among patients and internal medicine specialists. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02358-7

Vancouver

Jansen HI, Heuveling van Beek C, Bisschop PH, Heijboer AC, Bruinstroop E, Boelen A. The need for the GREAT+ score to predict relapse in Graves’ disease: a questionnaire among patients and internal medicine specialists. Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02358-7

BibTeX
@article{Jansen2024,
  author = {Jansen, H I and Heuveling van Beek, C and Bisschop, P H and Heijboer, A C and Bruinstroop, E and Boelen, A},
  title = {The need for the GREAT+ score to predict relapse in Graves’ disease: a questionnaire among patients and internal medicine specialists},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  doi = {10.1007/s40618-024-02358-7}
}
Kostenlos starten →